
PLx Pharma PLXP
Quarterly report 2022-Q3
added 11-10-2022
PLx Pharma Total Non Current Liabilities 2011-2025 | PLXP
Annual Total Non Current Liabilities PLx Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 34 M | 24.5 M | 7.21 M | 22.4 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 34 M | 7.21 M | 22 M |
Total Non Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
46.5 M | - | - | $ 142 M | ||
|
Assertio Holdings
ASRT
|
115 M | $ 0.73 | -3.54 % | $ 51.9 M | ||
|
Aerie Pharmaceuticals
AERI
|
274 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
104 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
7.44 M | - | 0.86 % | $ 117 M | ||
|
Cronos Group
CRON
|
10.7 M | $ 3.05 | -6.72 % | $ 1.63 B | ||
|
Agile Therapeutics
AGRX
|
16.4 M | - | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
681 M | $ 5.17 | -4.22 % | $ 86.3 M | ||
|
Catalent
CTLT
|
3.83 B | - | - | $ 11.5 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
316 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
38.2 M | - | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
26.4 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
36.6 M | - | -39.89 % | $ 27.7 M | ||
|
Organogenesis Holdings
ORGO
|
105 M | $ 4.78 | -0.83 % | $ 629 M | ||
|
Endo International plc
ENDP
|
8.8 B | - | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
1.02 B | $ 12.03 | 5.34 % | $ 616 M | ||
|
Pacira BioSciences
PCRX
|
368 M | $ 26.7 | 1.56 % | $ 1.23 B | ||
|
Evoke Pharma
EVOK
|
6.61 M | $ 10.97 | 0.18 % | $ 36.7 M | ||
|
Athenex
ATNX
|
157 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
134 M | $ 21.39 | 0.14 % | $ 2.04 B | ||
|
Rockwell Medical
RMTI
|
11.6 M | $ 0.87 | -5.71 % | $ 20.3 M | ||
|
Evolus
EOLS
|
102 M | $ 7.18 | 1.92 % | $ 445 M | ||
|
Harrow Health
HROW
|
19.8 M | $ 45.82 | -2.64 % | $ 1.49 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
991 K | $ 3.51 | -2.11 % | $ 4.36 M | ||
|
China Pharma Holdings
CPHI
|
1.71 M | $ 1.55 | -0.26 % | $ 27.1 M | ||
|
Bausch Health Companies
BHC
|
26.5 B | $ 6.88 | -0.65 % | $ 2.51 B | ||
|
Veru
VERU
|
6.71 M | $ 2.44 | 0.83 % | $ 329 M | ||
|
Lannett Company
LCI
|
677 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
107 M | $ 1.8 | -6.51 % | $ 402 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
23.9 M | $ 3.05 | 20.47 % | $ 42.9 M | ||
|
cbdMD
YCBD
|
2.49 M | $ 1.39 | 13.52 % | $ 5.99 M | ||
|
Neoleukin Therapeutics
NLTX
|
11.4 M | - | - | $ 193 M | ||
|
Solid Biosciences
SLDB
|
21.2 M | $ 5.81 | -1.11 % | $ 237 M | ||
|
PetIQ
PETQ
|
456 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
2.66 M | $ 4.32 | 6.4 % | $ 130 M | ||
|
Jupiter Wellness
JUPW
|
6.38 K | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
4.28 B | $ 12.86 | -2.17 % | $ 1.77 B | ||
|
ProPhase Labs
PRPH
|
7.94 M | $ 0.12 | 0.17 % | $ 1.9 M | ||
|
Radius Health
RDUS
|
200 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
111 M | - | -4.76 % | $ 65.3 M | ||
|
Sundial Growers
SNDL
|
1.03 M | $ 1.96 | -11.31 % | $ 3.37 M | ||
|
OptiNose
OPTN
|
130 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
53.4 M | $ 0.64 | -1.25 % | $ 30.6 M | ||
|
Tricida
TCDA
|
13.2 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
570 M | $ 11.6 | -4.56 % | $ 7.17 B | ||
|
TherapeuticsMD
TXMD
|
246 M | $ 1.69 | -3.43 % | $ 17.6 M | ||
|
Zomedica Corp.
ZOM
|
275 | - | -0.21 % | $ 98 M | ||
|
Viatris
VTRS
|
13.8 B | $ 11.66 | 0.09 % | $ 14.1 B |